Newron Pharmaceuticals SpA
SIX:NWRN
Operating Margin
Newron Pharmaceuticals SpA
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| IT |
|
Newron Pharmaceuticals SpA
SIX:NWRN
|
135.5m CHF |
51%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
731.4B USD |
40%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
393.8B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
45%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
205.6B CHF |
33%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
180.8B CHF |
33%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
159.6B GBP |
24%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
201.2B USD |
34%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
139.1B USD |
27%
|
Newron Pharmaceuticals SpA
Glance View
Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 25 full-time employees. The company went IPO on 2006-12-12. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Newron Pharmaceuticals SpA's most recent financial statements, the company has Operating Margin of 50.9%.
You don't have any saved screeners yet